Metabolic syndrome in HIV-infected individuals: Underlying mechanisms and epidemiological aspects

AIDS Research and Therapy

Volumn 10, Issue 1, 2013, Pages

  Paula, Adelzon A ^a   Falcão, Melissa C N ^a   Pacheco, Antonio G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

AIDS; Cardiovascular risk; HAART; HIV; Metabolic syndrome

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84890261324     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-10-32     Document Type: Review

References (81)

1. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, Guimaraes MR, Nunes EP, Lemos AS, Ribeiro SR, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: Shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 2013, 8:e59768. 10.1371/journal.pone.0059768, 3618173, 23577074.
2. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005, 6:99-106. 10.1111/j.1468-1293.2005.00271.x, 15807715.
3. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, Mercon M, Faulhaber JC, Harrison LH, Schechter M. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2009, 51:624-630. 10.1097/QAI.0b013e3181a4ecf5, 2748737, 19430304.
4. Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One 2008, 3:e1531. 10.1371/journal.pone.0001531, 2211396, 18231611.
5. Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, Saag MS, Mugavero MJ. HIV infection and obesity: Where did all the wasting go?. Antivir Ther 2012, 17:1281-1289. 10.3851/IMP2348, 3779137, 22951353.
6. Rosolova H, Nussbaumerova B. Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. EPMA J 2011, 2:15-26. 10.1007/s13167-011-0066-1, 3405365, 23199124.
7. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011, 34:216-219. 10.2337/dc10-0879, 3005489, 20889854.
8. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes 2008, 32(Suppl 2):S25-S29.
9. Westley RL, May FE. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol 2013, 2013:632461. 3747439, 23983688.
10. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010, 8:41. 10.1186/1741-7015-8-41, 2909929, 20591140.
11. Brumpton BM, Camargo CA, Romundstad PR, Langhammer A, Chen Y, Mai XM. Metabolic syndrome and incidence of asthma in adults: The HUNT study. Eur Respir J 2013,
12. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607. 10.2337/diab.37.12.1595, 3056758.
13. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442-443.
14. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection E, Treatment of High Blood Cholesterol in A.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005, 4:198-203. 10.1097/00132577-200512000-00018, 18340209.
16. Alberti KG, Zimmet P, Shaw J. Group IDFETFC: The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
17. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 2006, 4:79-85. 10.2174/157016206775197664, 16454713.
18. Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perre P, Leport C, Prazuck T, Jovelin T, Billard M, Sebille V, et al. Metabolic syndrome in French HIV-infected patients: Prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses 2012, 28:1672-1678. 10.1089/aid.2012.0048, 22731114.
19. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. Ethiop Med J 2012, 50:221-230.
20. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43:458-466. 10.1097/01.qai.0000243093.34652.41, 16980905.
21. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002, 25:1253-1254. 10.2337/diacare.25.7.1253, 12087038.
22. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132-137. 10.2337/diacare.28.1.132, 15616246.
23. Bonfanti P, Ricci E, De Socio G, Zeme D, Carradori S, Penco G, Parruti G, Grosso C, Madeddu G, Vichi F, et al. Metabolic syndrome: A real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128-131. 10.1097/01.qai.0000219775.20174.2d, 16763502.
24. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, De Villar NG, Zabena C, Fernandez C, Serrano-Rios M. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55:940-945. 10.1016/j.metabol.2006.02.024, 16784968.
25. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113-119. 10.2337/dc06-1075, 17192343.
26. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44:726-734. 10.1086/511679, 3170426, 17278068.
27. Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti S, Garzaniti A, Ciappina V, Maffezzini E, Maserati R, Filice G. High prevalence of metabolic syndrome among HIV-infected patients: Link with the cardiovascular risk. J Acquir Immune Defic Syndr 2002, 31:363-365. 10.1097/00126334-200211010-00015, 12439215.
28. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377-1382. 10.1097/00004872-200307000-00028, 12817187.
29. Bernal E, Masia M, Padilla S, Martin-Hidalgo A, Gutierrez F. Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort. Med Clin 2007, 128:172-175. quiz 171 p following 200.
30. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052. 10.1210/jc.74.5.1045, 1373735.
31. Vu CN, Ruiz-Esponda R, Yang E, Chang E, Gillard B, Pownall HJ, Hoogeveen RC, Coraza I, Balasubramanyam A. Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: Further evidence for a unique form of metabolic syndrome in HIV patients. Metabolism 2013, 62:1014-1020. 10.1016/j.metabol.2013.01.020, 23522788.
32. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58. 10.1097/00002030-199807000-00003, 9619798.
33. Kalantari P, Harandi OF, Hankey PA, Henderson AJ. HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. J Immunol 2008, 181:1548-1555. 2536764, 18606710.
34. Farhangi MA, Keshavarz SA, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi AA. White blood cell count in women: Relation to inflammatory biomarkers, haematological profiles, visceral adiposity, and other cardiovascular risk factors. J Health Popul Nutr 2013, 31:58-64. 3702359, 23617205.
35. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200. 10.1210/en.2003-0285, 12746274.
36. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
37. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 2008, 80:209-216. 10.1002/jmv.21114, 18098145.
38. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004, 18:1657-1669. 10.1096/fj.04-2204com, 15522911.
39. De Lorenzo F, Collot-Teixeira S, Boffito M, Feher M, Gazzard B, McGregor JL. Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: Rationale for preventative measures. Curr Med Chem 2008, 15:2991-2999. 10.2174/092986708786848668, 19075647.
40. Longenecker CT, Jiang Y, Yun CH, Debanne S, Funderburg NT, Lederman MM, Storer N, Labbato DE, Bezerra HG, McComsey GA. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013, 13:414-425.
41. Yerramasu A, Dey D, Venuraju S, Anand DV, Atwal S, Corder R, Berman DS, Lahiri A. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 2012, 220:223-230. 10.1016/j.atherosclerosis.2011.09.041, 22015177.
42. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. Am Heart J 2007, 153:907-917. 10.1016/j.ahj.2007.03.019, 17540190.
43. Ngatchou W, Lemogoum D, Ndobo P, Yagnigni E, Tiogou E, Nga E, Kouanfack C, Van de Borne P, Hermans MP. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naive HIV + patients from Cameroon. Vasc Health Risk Manag 2013, 9:509-516. 3772749, 24043942.
44. Maloberti A, Giannattasio C, Dozio D, Betelli M, Villa P, Nava S, Cesana F, Facchetti R, Giupponi L, Castagna F, et al. Metabolic Syndrome in Human Immunodeficiency Virus-Positive Subjects: Prevalence, Phenotype, and Related Alterations in Arterial Structure and Function. Metab Syndr Relat Disord 2013, 3:214-219.
45. Gibellini D, Miserocchi A, Tazzari PL, Ricci F, Clo A, Morini S, Ponti C, Pasquinelli G, Bon I, Pagliaro P, et al. Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells. J Cell Biochem 2012, 113:1132-1141. 10.1002/jcb.23446, 22095559.
46. Daniyam C, Iroezindu M. Lipid Profile of Anti-Retroviral Treatment-Naive HIV-Infected Patients in Jos, Nigeria. Ann Med Health Sci Res 2013, 3:26-30. 10.4103/2141-9248.109468, 3634219, 23634325.
47. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: The intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010, 87:589-598. 10.1189/jlb.0809580, 3085483, 19952353.
48. Giralt M, Domingo P, Guallar JP, De la Concepcion ML R, Alegre M, Domingo JC, Villarroya F. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antivir Ther 2006, 11:729-740.
49. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, Committee ITIC. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453. 10.1097/QAD.0b013e3282efad32, 18025881.
50. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Investigators HIVOS: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34. 10.1097/01.qai.0000233310.90484.16, 16878047.
51. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010, 201:1788-1795. 10.1086/652749, 2872049, 20446848.
52. De Luca A, De Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, Sighinolfi L, Giacometti A, Capobianchi MR ADA, et al. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case--control study. BMC Infect Dis 2013, 13:414. 10.1186/1471-2334-13-414, 3846422, 24004495.
53. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203. 10.1371/journal.pmed.0050203, 2570418, 18942885.
54. Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G, Arthos J. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004, 4:327-337. 10.1385/CT:4:4:327, 15531776.
55. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011, 32:945-951. 10.1093/eurheartj/ehq483, 3076665, 21228007.
56. Sabin CA, Worm SW. Conventional cardiovascular risk factors in HIV infection: How conventional are they?. Curr Opin HIV AIDS 2008, 3:214-219. 10.1097/COH.0b013e3282f6a613, 19372969.
57. Pacheco AGFGB, Fonseca MDJ, Moreira RI, Veloso VG, Friedman RK, Cardoso SW, Falcão M, Mil JG, Bensenor I, Lotufo P, Chor D. Carotid intima-media thickness (cIMT) in HIV-infected patients in Rio de Janeiro, Brazil: Overall and gender analysis 2013, Kuala Lumpur; Birmingham, AL, USA, 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention.
58. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chene G. Group ACA-CCS: Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012, 26:303-314. 10.1097/QAD.0b013e32834e8776, 22089377.
59. Blumer RM, Van Vonderen MG, Sutinen J, Hassink E, Ackermans M, Van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008, 22:227-236. 10.1097/QAD.0b013e3282f33557, 18097225.
60. Van Vonderen MG, Blumer RM, Hassink EA, Sutinen J, Ackermans MT, Van Agtmael MA, Yki-Jarvinen H, Danner SA, Serlie MJ, Sauerwein HP, Reiss P. Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy. J Acquir Immune Defic Syndr 2010, 53:186-193. 10.1097/QAI.0b013e3181c190f4, 19898246.
61. Palacios R, Merchante N, Macias J, Gonzalez M, Castillo J, Ruiz J, Marquez M, Gomez-Mateos J, Pineda JA, Santos J. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006, 11:529-535.
62. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254. 10.1074/jbc.C000228200, 10806189.
63. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr 2011, 57:284-289. 10.1097/QAI.0b013e318221863f, 21602696.
64. Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD. Antiretroviral drug levels and interactions affect lipid, lipoprotein, and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis. Metab Syndr Relat Disord 2007, 5:163-173. 10.1089/met.2006.0034, 2078603, 18007962.
65. Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, Caron M, Bastard JP. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005, 87:65-71. 10.1016/j.biochi.2004.12.007, 15733739.
66. Moog AM, Becker W. Management of dyslipidemia in HIV-infected patients. MMW Fortschr Med 2012, 154(Suppl 1):34-36.
67. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010, 17:491-501. 10.1097/HJR.0b013e328336a150, 20543702.
68. Pinto Neto LF, Das Neves MB, Ribeiro-Rodrigues R, Page K, Miranda AE. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz J Infect Dis 2013, 17:438-443. 10.1016/j.bjid.2012.12.006, 23735423.
69. Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Foca E, Motta D, Bellagamba R, Fezza R, Narciso P, et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naive patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials 2012, 13:245-255. 10.1310/hct1305-245, 23134625.
70. Dube MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807-1818. 10.1097/01.aids.0000183629.20041.bb, 16227788.
71. Souza SJ, Luzia LA, Santos SS, Rondo PH. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: A review. Rev Assoc Med Bras 2013, 59:186-198. 10.1016/j.ramb.2012.11.003, 23582562.
72. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: A systematic review. PloS One 2013, 8:e59551. 10.1371/journal.pone.0059551, 3608726, 23555704.
73. Vidrine DJ. Cigarette smoking and HIV/AIDS: Health implications, smoker characteristics and cessation strategies. AIDS Educ Prev 2009, 21:3-13.
74. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, Frank I, Tebas P. A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005, 39:557-561.
75. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT, Investigators H. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013, 10:E10. 3557014, 23347705.
76. Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clin Lipidol 2011, 6:447-462. 10.2217/clp.11.25, 3249059, 22216062.
77. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011, 6:e21843. 10.1371/journal.pone.0021843, 3134453, 21765919.
78. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193. 10.1097/00002030-200305230-00010, 12819520.
79. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62. 10.1056/NEJMra041811, 15635112.
80. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001, 15:2049-2051. 10.1097/00002030-200110190-00021, 11600837.
81. Thoni GJ, Fedou C, Brun JF, Fabre J, Renard E, Reynes J, Varray A, Mercier J. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002, 28:397-404.